These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10896229)

  • 1. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C.
    Sauleda S; Esteban JI; Altisent C; Puig L; Esteban R; Guardia J
    Thromb Haemost; 2000 Jun; 83(6):807-10. PubMed ID: 10896229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.
    Colombatto P; Civitano L; Oliveri F; Coco B; Ciccorossi P; Flichman D; Campa M; Bonino F; Brunetto MR
    Antivir Ther; 2003 Dec; 8(6):519-30. PubMed ID: 14760885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
    Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
    Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients.
    Santagostino E; De Filippi F; Rumi MG; Rivi M; Colombo M; Mannucci PM;
    Transfusion; 2004 May; 44(5):790-4. PubMed ID: 15104664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa.
    Fontaine H; Chaix ML; Lagneau JL; Bréchot C; Pol S
    Lancet; 2000 Jul; 356(9223):41. PubMed ID: 10892765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy.
    Rosen HR; Ribeiro RR; Weinberger L; Wolf S; Chung M; Gretch DR; Perelson AS
    J Hepatol; 2002 Jul; 37(1):124-30. PubMed ID: 12076871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers.
    Rumi MG; Santagostino E; Morfini M; Gringeri A; Tagariello G; Chistolini A; Pontisso P; Tagger A; Colombo M; Mannucci PM
    Blood; 1997 May; 89(10):3529-33. PubMed ID: 9160657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
    Schalm SW; Hansen BE; Chemello L; Bellobuono A; Brouwer JT; Weiland O; Cavalletto L; Schvarcz R; Ideo G; Alberti A
    J Hepatol; 1997 May; 26(5):961-6. PubMed ID: 9186825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?
    Turbide C; Soulellis C; Deschênes M; Hilzenrat N
    Can J Gastroenterol; 2008 Feb; 22(2):149-52. PubMed ID: 18299740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease.
    Lethagen S; Widell A; Berntorp E; Verbaan H; Lindgren S
    Br J Haematol; 2001 Apr; 113(1):87-93. PubMed ID: 11328286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressive symptoms and physical/mental functioning with interferon/ribavirin treatment of posttransplant recurrent hepatitis C.
    Bourgeois JA; Canning R; Suggett K; Chambers CC; Rahim N; Rossaro L
    Psychosomatics; 2006; 47(3):254-6. PubMed ID: 16684943
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders.
    Messick K; Sanders JC; Goedert JJ; Eyster ME
    Haemophilia; 2001 Nov; 7(6):568-74. PubMed ID: 11851755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of total dose of IFN in the treatment of chronic hepatitis C].
    Imazeki F; Yokosuka O
    Nihon Rinsho; 1994 Jul; 52(7):1794-7. PubMed ID: 7521420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.
    Akuta N; Suzuki F; Tsubota A; Suzuki Y; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2002 Dec; 37(6):831-6. PubMed ID: 12445425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.